Literature DB >> 22469356

Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension.

Alessandro Cataliotti, Lisa C Costello-Boerrigter, Horng H Chen, Stephen C Textor, John C Burnett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22469356      PMCID： PMC3497998          DOI： 10.1016/j.mayocp.2012.02.003

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  4 in total

1.  Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy.

Authors:  Paola Belluardo; Alessandro Cataliotti; Lorena Bonaiuto; Eliana Giuffrè; Egle Maugeri; Paola Noto; Giovanna Orlando; Giuseppa Raspa; Brigida Piazza; Luciano Babuin; Horng H Chen; Fernando L Martin; Paul M McKie; Denise M Heublein; John C Burnett; Lorenzo S Malatino
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04-28       Impact factor: 4.733

2.  Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats.

Authors:  Alessandro Cataliotti; Jason M Tonne; Diego Bellavia; Fernando L Martin; Elise A Oehler; Gerald E Harders; Jarryd M Campbell; Kaw-Whye Peng; Stephen J Russell; Lorenzo S Malatino; John C Burnett; Yasuhiro Ikeda
Journal:  Circulation       Date:  2011-03-14       Impact factor: 29.690

3.  Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure.

Authors:  Alessandro Cataliotti; John A Schirger; Fernando L Martin; Horng H Chen; Paul M McKie; Guido Boerrigter; Lisa C Costello-Boerrigter; Gail Harty; Denise M Heublein; Sharon M Sandberg; Kenneth D James; Mark A Miller; Navdeep B Malkar; Karen Polowy; John C Burnett
Journal:  Circulation       Date:  2005-08-01       Impact factor: 29.690

4.  Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure.

Authors:  Horng H Chen; Margaret M Redfield; Lynda J Nordstrom; Darlene P Horton; John C Burnett
Journal:  J Card Fail       Date:  2004-04       Impact factor: 5.712
  4 in total
  16 in total

1.  Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis.

Authors:  Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

2.  B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension.

Authors:  Sara J Holditch; Claire A Schreiber; Ryan Nini; Jason M Tonne; Kah-Whye Peng; Aron Geurts; Howard J Jacob; John C Burnett; Alessandro Cataliotti; Yasuhiro Ikeda
Journal:  Hypertension       Date:  2015-05-11       Impact factor: 10.190

3.  A gut-heart connection in cardiometabolic regulation.

Authors:  Alessia Buglioni; John C Burnett
Journal:  Nat Med       Date:  2013-05       Impact factor: 53.440

Review 4.  Natriuretic peptides in cardiometabolic regulation and disease.

Authors:  Nora E Zois; Emil D Bartels; Ingrid Hunter; Birgitte S Kousholt; Lisbeth H Olsen; Jens P Goetze
Journal:  Nat Rev Cardiol       Date:  2014-05-13       Impact factor: 32.419

Review 5.  Natriuretic Peptides as a Novel Target in Resistant Hypertension.

Authors:  Pratik Patel; Horng H Chen
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

6.  Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP.

Authors:  Fima Macheret; Denise Heublein; Lisa C Costello-Boerrigter; Guido Boerrigter; Paul McKie; Diego Bellavia; Sarah Mangiafico; Yasuhiro Ikeda; Kent Bailey; Christopher G Scott; Sharon Sandberg; Horng H Chen; Lorenzo Malatino; Margaret M Redfield; Richard Rodeheffer; John Burnett; Alessandro Cataliotti
Journal:  J Am Coll Cardiol       Date:  2012-10-16       Impact factor: 24.094

7.  Retraction. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis.

Authors:  Ming-Yi Lv; Shu-Ling Deng; Xiao-Feng Long
Journal:  Br J Clin Pharmacol       Date:  2015-11-28       Impact factor: 4.335

8.  Is natriuretic peptide receptor C a new target for hypertension therapeutics?

Authors:  Yanfei Qi; Mohan K Raizada
Journal:  Hypertension       Date:  2014-01-27       Impact factor: 10.190

Review 9.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

Review 10.  Emerging concepts for patients with treatment-resistant hypertension.

Authors:  Alfonso Eirin; Stephen C Textor; Lilach O Lerman
Journal:  Trends Cardiovasc Med       Date:  2016-05-17       Impact factor: 6.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.